Orion Oyj (ORINY)

Market Cap	10.94B
Revenue (ttm)	1.72B
Net Income (ttm)	375.49M
Shares Out	n/a
EPS (ttm)	2.67
PE Ratio	29.14
Forward PE	22.65
Dividend	0.46 (1.18%)
Ex-Dividend Date	Apr 7, 2025

Volume	263
Average Volume	119
Open	39.11
Previous Close	39.39
Day's Range	39.11 - 39.11
52-Week Range	21.10 - 39.47
Beta	0.37
RSI	77.53
Earnings Date	Jul 18, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,880
• Stock Exchange: OTCMKTS
• Ticker Symbol: ORINY

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.

Financial numbers in EUR